We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

J&J Unit Slams Diabetes Drug Blood Disorder Claims

Law360, Philadelphia (March 8, 2016, 5:07 PM EST) -- A Johnson & Johnson unit has hit back at allegations that its Type 2 diabetes drug Invokana caused a man to contract the potentially life-threatening condition diabetic ketoacidosis, telling a Pennsylvania court that his drug design defect claims were federally preempted.

In Feb. 29 preliminary objections to the complaint, Janssen Pharmaceuticals Inc. pointed to a trio of U.S. Supreme Court rulings that purportedly clarified the test for preemption issues, saying that the principles expressed applied to both branded and generic drugs.

“First, courts should identify what...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.